What is mimedx group? MiMedx Group is a biomedical company based in Marietta, Georgia, founded in 2008. It is traded on the NASDAQ as MDXG. The CEO is Tim Wright. Using tissues from birth such as the placenta, amniotic sac, and umbilical cord, MiMedx creates skin for skin grafts .Why mimimedx for amniotic tissue? MiMedx is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.What manufacturing practices does mimedx use to produce its allografts? We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MiMedx has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.What happened to mimedx and organogenesis? In December 2014, MiMedx sued Organogenesis for interfering in its VA business, but withdrew the suit a month later. In 2016, a VA rule change on the storage of medical products meant MiMedx would have to take product back, causing a revenue drop since the sales were already booked.
AMNIOFIX is SMR 2 T Technology (Selective Membrane of Reparative and Reconstructive Tissue) which provides a semi-permeable protective barrier that supports the healing cascade. The product protects the wound bed to aid in the development of granulation tissue and provides a human biocompatible extracellular matrix that retains 300+ regulatory
MiMedX Group's products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. It sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally.